AI litigation brief
Ozempic NAION remains early-stage / active mdl with 9 current signals in the accepted feed.
Overview
PubMed research on Mar 10: Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.. This is the lead item in the current accepted signal set.
Key developments
- PACER court filing on Mar 10: BARZYZ v. NOVO NORDISK INC.
- PubMed research on Mar 10: Ischemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.
Trajectory
Ozempic NAION is moving on the court side on MDL 3163 — docket scheduling and case-management orders should lead the next editorial update.
Editorial intelligence
MDL 3163 should stay on the lead docket watch because it is the primary consolidation vehicle for Ozempic NAION.
Generated Mar 11, 2026, 10:16 PM UTC